Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

The global demand for healthcare and biotech products continues to grow, owing to factors such as increasing chronic diseases and a greater focus on personalized medicine. Therefore, it might be wise to check out fundamentally sound biotech stocks BioMarin Pharmaceutical (BMRN), Exelixis, Inc. (EXEL), and Theratechnologies (THTX), currently trading at…

StockNews.com

Axsome Therapeutics Expects Up To $11.5 Billion In Peak Sales, Wallops Analysts' Forecasts

Axsome expects its eight products to generate up to $11.5 billion in peak U.S. sales. AXSM stock zoomed higher Wednesday.

Investors Business Daily

Tilray Brands (TLRY) vs. Novo Nordisk (NVO): Which Pharma Stock Should You Buy?

The pharmaceutical sector performs relatively well during economic uncertainties due to inelastic demand for its products and services. While prominent players Tilray Brands (TLRY) and Novo Nordisk (NVO) should benefit, which stock is the better buy now? Read more to find out.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Macron promises to bring pharmaceutical production 'back home' to France

French President Emmanuel Macron has vowed to relocate the production of 50 key pharmaceutical drugs, 25 of them - in the coming weeks - to tackle an ongoing shortage of medicines in France.

Radio France Internationale

One Of The Biggest Names In Medicine Just Entered The Obesity Melee. Here's Why Novo, Lilly Still Have An Edge.

Pharma giant Merck unveiled new data for a potential competitor to weight loss drugs from Novo Nordisk and Eli Lilly.

Investors Business Daily

Should You Buy Into Pfizer (PFE) Today?

Despite a slowdown of Covid-19 vaccine sales in the last reported quarter, biopharmaceutical giant Pfizer (PFE) is positioned to deliver robust growth this year and beyond, thanks to the strength of its in-line products and expected near-term launches and revenue distribution from the recent acquisition. So, let’s find out if…

StockNews.com

2 Game-Changing Biotech Stocks, 1 to Sell Now

As the biotech industry looks well-positioned for solid growth driven by strong government support and a growing foothold of personalized medicines, it could be wise for investors to buy fundamentally strong biotech stocks Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN). However, fundamentally weak Titan Pharmaceuticals (TTNP) might be best avoided.…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Pharma firm Quantum sees big increase in revenues and profits

The County Durham company said it was focussed on growth after a successful year

Birmingham Post

Is Catalyst Pharmaceuticals (CPRX) a Buy in the Near Future?

Catalyst Pharmaceuticals (CPRX) witnessed significant bottom-line growth in the first quarter but missed expectations. Does the biopharmaceutical company deserve a place in your portfolio in the near future? Let’s look at its financial metrics to get an idea….

StockNews.com

Advocating for climate justice

As part of a weekly showcase of future leaders and inspirational young New Zealanders from the Hyundai Pinnacle Programme, Isla Day wants to develop better connections between industry and academia in the field of drug development – and fight for climate justice | Content Partnership

Newsroom.co.nz

Biogen Rises After 'Drama-Free' Panel Votes Unanimously In Support Of Alzheimer's Drug

Biogen stock rose Monday after a panel of advisors to the FDA voted unanimously in favor of its newest Alzheimer's treatment.

Investors Business Daily

Why Perfectly Rated Disc Medicine, With A 287% Move This Year, Just Put Up Another Big Gain

Disc Medicine said Friday its drug improved symptoms for patients with sunlight intolerance. The highly rated biotech stock soared.

Investors Business Daily

3 Medical Stock Picks for Investors

As the demand for healthcare products and solutions continues to rise, the medical industry is poised for remarkable growth. Therefore, quality medical stocks Johnson & Johnson (JNJ), AstraZeneca (AZN), and Astellas Pharma (ALPMY) could be the ideal investments for your portfolio amid current market uncertainties. Read on….

StockNews.com

Buy, Hold or Sell? Gilead Sciences Inc. (GILD) and Moderna Inc. (MRNA)

Rapid breakthroughs and surging demand position the biotech sector for significant expansion in the near term. Therefore, quality biotech stock Gilead Sciences (GILD) could be worth buying. However, I think it will be best to wait for a better entry point in Moderna (MRNA). Read on.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

The Hindu

Construction of ₹500-cr. pharma glass tubing unit begins in Telangana

Production of the Velocity Vials at SGD Pharma’s facility in Vemula is expected to begin in the first quarter of 2024 whereas that of the pharmaceutical tubing will begin in 2025.

Salon

Merck sues to block lower Medicare costs

The company claims that the plan to allow Medicare to negotiate drug prices violates the First and Fifth Amendments

Investors Business Daily

Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near

Biogen stock rose Wednesday after the FDA posted documents that suggest the agency will approve Alzheimer's treatment Leqembi.

StockNews.com

Which Pharma Stock is a Pick for June: Pfizer (PFE) or SNDL Inc. (SNDL)?

The pharmaceutical industry is known for its resilience during challenging economic times, primarily due to the inelastic demand for essential medicines. As the specter of a potential recession hangs over the market, let us analyze two leading players in the sector, Pfizer (PFE) and SNDL (SNDL), to find the better…

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Merck sues federal government, calling plan to negotiate Medicare drug prices 'extortion'

Merck is suing the federal government over a plan to negotiate Medicare drug prices, calling the program a sham equivalent to extortion

Investors Business Daily

Merck Delivers First Legal Blow To Biden's Medicare Negotiation Plan, Calling It A 'Sham'

Merck sued the Biden administration Tuesday, saying a drug-pricing law is a "sham." The legal battle will impact pharmaceutical stocks.

StockNews.com

3 Pharmaceutical Stocks to Watch

The pharmaceutical industry is anticipated to grow due to rising chronic diseases and an aging population. Given the industry's strong long-term prospects, quality stocks Novo Nordisk (NVO), Novartis (NVS), and Bristol-Myers Squibb (BMY) could be worth adding to your watchlist. Continue reading….

Birmingham Post

Magnitude Biosciences seals £500,000 investment to ramp up research work

It has secured a Future Economy Investor Partnerships grant from Innovate UK which has been match funded by the North East Innovation Fund

Kiplinger

Is a Possible Delta-8 THC Ban in the Works? This Week in Cannabis Investing

The Drug Enforcement Agency is reportedly planning to reschedule many hemp-derived cannabinoids, including delta-8 THC.

Investors Business Daily

IBD 50 Stock Hits All-Time High, And 44% EPS Growth Expected

This drug stock ranks first out of 790 medical stocks and is in the buy zone. The company plans to roll out its overdose nasal spray in the third quarter.

The Independent UK

Supreme Court revives claims that SuperValu, Safeway overcharged governments for generic drugs

The Supreme Court has unanimously revived whistleblower lawsuits claiming that supermarket and pharmacy chains SuperValu and Safeway overcharged government health-care programs for prescription drugs by hundreds of millions of dollars

1 … 33 34 35 36

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.